A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
Pengfei Wang, Ryan G. Casner, Manoj S. Nair, Jian Yu, Yicheng Guo, Maple Wang, Jasper Fuk‐Woo Chan, Gabriele Cerutti, Sho Iketani, Lihong Liu, Zizhang Sheng, Zhiwei Chen, Kwok‐Yung Yuen, Peter D. Kwong, Yaoxing Huang, Lawrence Shapiro, David D. Ho
Abstract
and confirmed that K378 T in SARS-CoV-2 RBD led to viral resistance. Taken together, 2-36 represents a strategic reserve drug candidate for the prevention and treatment of possible diseases caused by pre-emergent SARS-related coronaviruses. Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine.
Topics & Concepts
Monoclonal antibodyVirologyEpitopeAntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyEpitope mappingCoronavirusCoronavirus disease 2019 (COVID-19)ImmunologyMedicineInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesViral gastroenteritis research and epidemiology